Meeting
2019 ASCO Annual Meeting
THOR-707: Using synthetic biology to reprogram the therapeutic activity of interleukin-2 (IL-2).
Authors
Marcos E Milla
Synthorx Inc. Research & Development, La Jolla, CA
Marcos E Milla , Jerod Ptacin , Carolina E. Caffaro , Hans R. Aerni , Lina Ma , Lilia Koriazova , Ingrid B. Joseph , Laura K. Shawver
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2603)
DOI
10.1200/JCO.2019.37.15_suppl.2603
Abstract #
2603
Poster Bd #
247
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.
First Author: Paolo Antonio Ascierto
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess
Poster
2018 ASCO Annual Meeting
TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.
First Author: Jie Yu
Poster
2017 ASCO Annual Meeting
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
First Author: Chantale Bernatchez